Find therapies in clinical trials near you – page 2

Study of PSMA PET imaging versus standard imaging to guide radiation therapy in patients with intermediate or high-risk prostate cancer

Study of PSMA PET imaging versus standard imaging to guide radiation therapy in patients with intermediate or high-risk prostate cancer

Study of JSB462 and lutetium (177Lu) vipivotide tetraxetan combination for adult men with PSMA-positive metastatic castration resistant prostate cancer

Study of JSB462 and lutetium (177Lu) vipivotide tetraxetan combination for adult men with PSMA-positive metastatic castration resistant prostate cancer

Study on the Use of 18F-PSMA-1007, Piflufolastat (18F), and Gozetotide for Detecting Pelvic Lymph Node Invasion in Newly Diagnosed Prostate Cancer Patients

Study on the Use of 18F-PSMA-1007, Piflufolastat (18F), and Gozetotide for Detecting Pelvic Lymph Node Invasion in Newly Diagnosed Prostate Cancer Patients

Study on Treating Metastatic Castration-Resistant Prostate Cancer with 177Lu-PNT2002 Compared to Abiraterone or Enzalutamide for Patients After Hormonal Therapy

Study on Treating Metastatic Castration-Resistant Prostate Cancer with 177Lu-PNT2002 Compared to Abiraterone or Enzalutamide for Patients After Hormonal Therapy

Evaluation of PSMA PET/CT Imaging for Lymph Node Assessment in Patients with Intermediate and High-Risk Non-Metastatic Prostate Cancer Before Surgery

Evaluation of PSMA PET/CT Imaging for Lymph Node Assessment in Patients with Intermediate and High-Risk Non-Metastatic Prostate Cancer Before Surgery

Study on the Safety and Effects of Lutetium (177Lu) Vipivotide Tetraxetan in Adults with Metastatic Castration-Resistant Prostate Cancer

Study on the Safety and Effects of Lutetium (177Lu) Vipivotide Tetraxetan in Adults with Metastatic Castration-Resistant Prostate Cancer

Study Comparing 177Lu-PSMA-617 with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

Study Comparing 177Lu-PSMA-617 with Standard Treatment for Men with Metastatic Hormone-Sensitive Prostate Cancer

Study on Lutetium (177Lu) Vipivotide Tetraxetan for Men with Progressive Metastatic Castration-Resistant Prostate Cancer

Study on Lutetium (177Lu) Vipivotide Tetraxetan for Men with Progressive Metastatic Castration-Resistant Prostate Cancer

Study on the Safety and Effects of Lutetium (177Lu) Vipivotide Tetraxetan in Patients with Advanced Prostate Cancer and Different Levels of Kidney Function

Study on the Safety and Effects of Lutetium (177Lu) Vipivotide Tetraxetan in Patients with Advanced Prostate Cancer and Different Levels of Kidney Function

Study on Lutetium (177Lu) Vipivotide Tetraxetan and Androgen Receptor Inhibitors for Patients with Castration-Resistant Prostate Cancer

Study on Lutetium (177Lu) Vipivotide Tetraxetan and Androgen Receptor Inhibitors for Patients with Castration-Resistant Prostate Cancer

Study of [225Ac]Ac-PSMA-R2 for Men with Advanced Prostate Cancer Previously Treated or Not with 177Lu-PSMA Therapy